Register now to secure your place at a new free-to-attend webinar on 23 September entitled ‘PROTAC-Mediated CDK2 degradation in oncology: Immunoassay tools for therapeutic discovery’, hosted by DDW and supported by Revvity. Audrey Johnson, a scientist at Beantown Biotech, explores the innovative application of targeted… Read More
Register now to secure your place at a new free-to-attend webinar on 23 September entitled ‘PROTAC-Mediated CDK2 degradation in oncology: Immunoassay tools for therapeutic discovery’, hosted by DDW and supported by Revvity. Audrey Johnson, a scientist at Beantown Biotech, explores the innovative application of targeted… Read More
Register now to secure your place at a new free-to-attend webinar on 23 September entitled ‘PROTAC-Mediated CDK2 degradation in oncology: Immunoassay tools for therapeutic discovery’, hosted by DDW and supported by Revvity. Audrey Johnson, a scientist at Beantown Biotech, explores the innovative application of targeted… Read More
Register now to secure your place at a new free-to-attend webinar on 23 September entitled ‘PROTAC-Mediated CDK2 degradation in oncology: Immunoassay tools for therapeutic discovery’, hosted by DDW and supported by Revvity. Audrey Johnson, a scientist at Beantown Biotech, explores the innovative application of targeted… Read More
Register now to secure your place at a new free-to-attend webinar on 23 September entitled ‘PROTAC-Mediated CDK2 degradation in oncology: Immunoassay tools for therapeutic discovery’, hosted by DDW and supported by Revvity. Audrey Johnson, a scientist at Beantown Biotech, explores the innovative application of targeted… Read More
In this webinar, hosted by DDW and supported by Revvity, Audrey Johnson, a scientist at Beantown Biotech, explores the innovative application of targeted protein degradation (TPD) in oncology research, with a specific focus on CDK2 degradation for potential cancer treatments. Johnson is joined during the Q&A by Rachel Mendes, Senior… Read More
